Rotigotine

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Restless Legs Syndrome

Conditions

Restless Legs Syndrome

Trial Timeline

Jul 1, 2003 → Apr 1, 2009

NCT ID

NCT00498186

About Rotigotine

Rotigotine is a phase 2 stage product being developed by UCB for Restless Legs Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00498186. Target conditions include Restless Legs Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03103919	Approved	Completed	Mar 16, 2017	Jan 2, 2018	Parkinson´s Disease
NCT01976871	Approved	Completed	Aug 1, 2014	Dec 1, 2015	Restless Legs Syndrome
NCT01782222	Approved	Completed	Feb 1, 2013	Mar 1, 2014	Idiopathic Parkinson's Disease
NCT01723904	Phase 3	Completed	Oct 1, 2012	Apr 1, 2013	Advanced Parkinson's Disease
NCT01711866	Approved	Completed	Sep 1, 2012	Mar 1, 2013	Advanced Idiopathic Parkinson's Disease
NCT01569464	Phase 3	Completed	Mar 1, 2012	Apr 1, 2013	Restless Legs Syndrome
NCT01498120	Phase 2	Completed	Dec 1, 2011	Dec 1, 2015	Restless Legs Syndrome
NCT01495793	Phase 2	Completed	Dec 1, 2011	May 1, 2014	Restless Legs Syndrome
NCT01300819	Approved	Completed	Feb 1, 2011	Nov 1, 2012	Idiopathic Parkinson's Disease
NCT00594464	Approved	Completed	Sep 1, 2007	May 1, 2008	Parkinson's Disease
NCT00593606	Phase 3	Completed	Jul 1, 2007	Dec 1, 2007	Parkinson's Disease
NCT00519532	Phase 3	Terminated	Jul 1, 2007	May 1, 2009	Parkinson's Disease
NCT00474058	Phase 3	Completed	May 1, 2007	Mar 1, 2009	Parkinson's Disease
NCT01964573	Phase 1	Completed	Dec 1, 2006	Feb 1, 2007	Parkinson's Disease
NCT00498108	Phase 3	Completed	Jan 1, 2006	Sep 1, 2007	Idiopathic Restless Legs Syndrome
NCT00263068	Phase 3	Completed	Dec 1, 2005	Dec 1, 2007	Restless Legs Syndrome
NCT00275236	Phase 3	Completed	Nov 1, 2005	Jul 1, 2006	Restless Legs Syndrome
NCT00135993	Phase 3	Completed	May 1, 2005	Nov 1, 2006	Restless Legs Syndrome
NCT00136045	Phase 3	Completed	May 1, 2005	Aug 1, 2006	Restless Legs Syndrome
NCT00505687	Phase 3	Completed	Feb 1, 2005	Dec 1, 2008	Idiopathic Parkinson's Disease

Competing Products

20 competing products in Restless Legs Syndrome

See all competitors

Product	Company	Stage	Hype Score
Gabapentin enacarbil	Astellas Pharma	Approved	85
ASP8825	Astellas Pharma	Phase 3	77
Regnite	Astellas Pharma	Pre-clinical	23
ASP8825 + Placebo	Astellas Pharma	Phase 2	52
Placebo + Gabapentin enacarbil	Astellas Pharma	Approved	85
Apomorphine Sublingual Film + Placebo	Sumitomo Pharma	Approved	85
Suvorexant	Merck	Approved	85
Cabergoline	Pfizer	Phase 3	76
Placebo + pregabalin + pregabalin	Pfizer	Phase 3	76
placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + Pregabalin	Pfizer	Phase 2	51
pregabalin + placebo + pramipexole	Pfizer	Phase 3	76
placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexol	Pfizer	Phase 3	76
cabergoline + levodopa	Pfizer	Phase 3	76
Rotigotine	UCB	Phase 3	74
Neupro®	UCB	Pre-clinical	20
Rotigotine Nasal Spray	UCB	Phase 2	49
Rotigotine	UCB	Phase 3	74
Levetiracetam (Keppra)	UCB	Phase 2	49
Rotigotine + Placebo	UCB	Approved	82
Rotigotine	UCB	Phase 3	74

Other Products from UCB

LevetiracetamApproved

Parcopa + carbidopa-levodopa (Sinemet)Approved

LevocetirizineApproved

RotigotineApproved

Levetiracetam + OxcarbazepineApproved